Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine
The first cases of pandemic influenza A (H1N1) 2009 infection were seen in Mexico in March 2009. Since then, it is thought to have been responsible for at least 18,337 deaths globally. Owing to the young age of fatalities, there have been an estimated 2 million years of life lost, which is comparable to the previous pandemics of 1957 and 1968. In this article, we consider the available data on a monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine, Pandemrix™ (GlaxoSmithKline, Rixensart, Belgium). At present, Pandemrix appears to be highly immunogenic in all age groups, including children and infants under 3 years of age, with an acceptable safety profile in the context of an influenza pandemic. However, owing to the novel adjuvant, further studies on the safety, immunogenicity and vaccine effectiveness of Pandemrix together with robust post-marketing surveillance are required.
1385-1398
Walker, Woolf T.
b9981f69-8c4e-441d-93d7-d45e65341576
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
December 2010
Walker, Woolf T.
b9981f69-8c4e-441d-93d7-d45e65341576
Faust, Saul N.
f97df780-9f9b-418e-b349-7adf63e150c1
Walker, Woolf T. and Faust, Saul N.
(2010)
Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
Expert Review of Vaccines, 9 (12), .
(doi:10.1586/erv.10.141).
(PMID:21105775)
Abstract
The first cases of pandemic influenza A (H1N1) 2009 infection were seen in Mexico in March 2009. Since then, it is thought to have been responsible for at least 18,337 deaths globally. Owing to the young age of fatalities, there have been an estimated 2 million years of life lost, which is comparable to the previous pandemics of 1957 and 1968. In this article, we consider the available data on a monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine, Pandemrix™ (GlaxoSmithKline, Rixensart, Belgium). At present, Pandemrix appears to be highly immunogenic in all age groups, including children and infants under 3 years of age, with an acceptable safety profile in the context of an influenza pandemic. However, owing to the novel adjuvant, further studies on the safety, immunogenicity and vaccine effectiveness of Pandemrix together with robust post-marketing surveillance are required.
This record has no associated files available for download.
More information
Published date: December 2010
Identifiers
Local EPrints ID: 175587
URI: http://eprints.soton.ac.uk/id/eprint/175587
ISSN: 1476-0584
PURE UUID: 3810df2a-fd22-44c1-9b15-edf28a814da0
Catalogue record
Date deposited: 24 Feb 2011 15:06
Last modified: 14 Mar 2024 02:51
Export record
Altmetrics
Contributors
Author:
Woolf T. Walker
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
